Botulinum antitoxin heptavalent

Drug Profile

Botulinum antitoxin heptavalent

Alternative Names: BAT; Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)(Equine); H-BAT™

Latest Information Update: 10 Feb 2016

Price : $50

At a glance

  • Originator Cangene Corporation
  • Developer Emergent BioSolutions
  • Class Antitoxins; Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Botulism
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Botulism

Most Recent Events

  • 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
  • 25 Mar 2013 Registered for Botulism (in adults and children) in USA (IV)
  • 12 Feb 2013 PDUFA action date of 22/03/2013 assigned by US FDA for Botulism antitoxin heptavalent for Botulism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top